Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI) (PRECISE)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: January 7, 2011
Last updated: January 12, 2012
Last verified: January 2012
The objective of this study is to evaluate the safety and effectiveness of the clinical and technical performance of the CorPath® 200 System in the delivery and manipulation of coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).
Coronary Artery Disease
Arterial Occlusive Diseases
Device: CorPath 200 System
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Primary Outcome Measures:
- Clinical Procedural Success [ Time Frame: 48-hrs or hospital discharge, whichever occurs first ] [ Designated as safety issue: Yes ]
Defined as <30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.
- Device Technical Success [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]
Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||December 2011 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
General Inclusion Criteria:
- Subject is between 18 and 99 years of age.
- Subject is an acceptable candidate for PCI.
- Subject must have clinical evidence of ischemic heart disease or a positive functional study.
- Female subjects must be of non-child bearing potential, or if able to bear children, have a negative pregnancy test within 7 days prior to the CorPath procedure.
- The subject or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
Angiographic Inclusion Criteria:
- Study lesion is a single de novo native coronary artery lesion. This lesion may consist of multiple lesions (with 10mm or less between diseased segments) and must be completely covered by a single stent with at least 2.0mm of normal segments on proximal and distal edges of the lesion.
- Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.
- Study lesion length is less than or equal to 24.0mm by visual estimate.
- Study lesion diameter showing stenosis of at least 50% by visual estimate.
General Exclusion Criteria:
- Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days following the CorPath procedure.
- Evidence of an acute myocardial infarction within 72 hours prior to the intended CorPath procedure.
- Subject has documented left ventricular ejection fraction <30%.
- Subject has undergone PCI within 72 hours prior to the CorPath procedure.
- Subject has undergone PCI within 30 days prior to the CorPath procedure and experienced a major adverse coronary event (MACE) or a serious adverse event (SAE) as defined in the protocol.
- Subject has known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel, stainless steel, cobalt chromium, or sensitivity to contrast media, including Visipaque™, which cannot be adequately pre-medicated or managed with clinically appropriate substitutes.
- Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, or a WBC count of <3,000 cells/mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or leukopenia).
- Subject has a serum creatinine level of >2.0 mg/dL or eGFR <30 ml/min as measured within 7 days prior to the procedure.
- Subject has suffered a stroke within 30 days prior to planned CorPath procedure.
- Subject has an active peptic ulcer or upper gastrointestinal bleeding within the 6 months prior to planned CorPath procedure.
- Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Subject is currently participating in another investigational drug or drug/device or device trial and has not completed the entire follow up period.
- Femoral access is not possible.
Angiographic Exclusion Criteria:
- Target lesion that cannot be fully covered by a single stent.
- Subject requires treatment of more than one vessel.
- Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.
- The study lesion requires planned treatment with directional coronary atherectomy (DCA), laser, rotational atherectomy or any device except for balloon dilatation prior to stent placement.
- The study vessel has evidence of intraluminal thrombus.
- The study vessel has evidence of moderate to severe tortuosity (>90°) proximal to the target lesion.
The study lesion has any of the following characteristics:
- Total occlusion.
- Ostial location.
- Is within 2.0 mm of a side branch measuring >2.0 mm in diameter.
- Located at < 45° bend in the vessel.
- Moderately to severely calcified.
- Moderate to severe calcification in the vessel proximal to the target lesion.
- Located in a native vessel distal to an anastomosis, with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached through the bypass graft.
- Unprotected left main coronary artery disease defined as an obstruction greater than 50% diameter stenosis in the left main coronary artery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01275092
|Washington Hospital Center
|Washington, District of Columbia, United States, 20010 |
|Northeast Georgia Heart Center
|Gainesville, Georgia, United States, 30501 |
|St. Elizabeth's Medical Center
|Boston, Massachusetts, United States, 02135 |
|Columbia University Medical Center
|New York, New York, United States, 10032 |
|Saint Joseph's Hospital
|Syracuse, New York, United States, 13203 |
|Wellmont CVA Heart Institute
|Kingsport, Tennessee, United States, 37660 |
|Virginia Commonwealth University
|Richmond, Virginia, United States, 23298 |
|Swedish Medical Center
|Seattle, Washington, United States, 98122 |
|Medellin, Colombia |
||Michail Pankratov, MD/PhD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 7, 2011
||January 12, 2012
||United States: Food and Drug Administration
Keywords provided by Corindus Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 19, 2013
Arterial Occlusive Diseases
Coronary Artery Disease